Antibody Discovery and Development for COVID-19 Diagnostic Testing

Use synthetic biology to rapidly discover antibodies that target SARS-CoV-2 proteins
Characterize binding kinetics, affinity, and epitope specificity on large antibody libraries
Accelerate library-to-lead triage

Twist Biopharma is using its proprietary platform to produce and discover highly specific antibodies against SARS-CoV-2 proteins, which can be used for developing a diagnostic testing product.

Learn how Twist Biopharma uses the Carterra LSA high-throughput surface plasmon resonance (SPR) platform to bypass ELISA screening and proceed directly to binding kinetics and epitope binning after panning. Aaron and Noah explain in detail how the LSA helps consolidate mAb workflows and reduces the time to answer.

Presented by:
Noah T. Ditto, Technical Product Manager, Carterra
Aaron Sato, PhD, CSO, Biopharma, Twist Bioscience